European Commission approves subcutaneous RYBREVANT®▼ (amivantamab) for the treatment of patients with advanced EGFR mutated non small cell lung cancer (Johnson & Johnson)

Posted 2025-04-07, Public Technologies Headlines

) FOR EUROPEAN MEDICAL AND TRADE MEDIA ONLY Media contact: Zayn Qureshi [email protected] Investor contact: Lauren Johnson [email protected] For Immediate Release European Commission approves subcutaneous RYBREVANT®▼ (amivantamab) for the treatment of... read full story

Ask about this article

Answer for your question of the article will be displayed here ...